Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Troubled XOMA Nails Immuno-Oncology Pact Worth $530 Million+ With Novartis

BERKELEY, Calif. – Swiss-based Novartis AG (NVS) struck a deal worth more than $500 million with XOMA Corporation (XOMA) to acquire rights to the company’s anti-transforming growth factor-beta (TGFb) antibody program, Xoma announced this morning. Under terms of the deal, Xoma will receive $37 million in upfront payments, with the remaining $480 million in regulatory […]

Read More »

Germany’s Merck sells rights to Kuvan back to BioMarin Pharma

Germany’s Merck KGaA said it agreed to return to BioMarin Pharmaceutical Inc the rights to the Kuvan drug against rare genetic disorder PKU as it seeks to focus on cancer, immunology and neurology. Merck in 2005 acquired the rights to Kuvan and Peg-Pal, another PKU treatment, outside the United States and Japan. Under the agreement […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom